{"DataElement":{"publicId":"7580673","version":"1","preferredName":"Prior CAR T-Lymphocyte Therapy Administered Prior Therapy Agent Type","preferredDefinition":"information related to the prior therapy administered._A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell._A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc._Prior action or administration of therapeutic agents that produced an effect that is intended to alter or stop a pathologic process._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)_The words or language units by which a thing is known._Something distinguishable as an identifiable class based on common qualities.","longName":"PRI_CART_THPY_ADM_TYP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7580672","version":"1","preferredName":"Prior CAR T-Lymphocyte Therapy Administered","preferredDefinition":"information related to the prior therapy administered._A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell._A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.","longName":"PRIOR_CART_TX_ADM","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"7580670","version":"1","preferredName":"Prior Chimeric Antigen Receptor T-Lymphocyte Therapeutic Procedure","preferredDefinition":"Earlier in time or order.:A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell.:A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","longName":"C25629:C126108:C12476:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Chimeric Antigen Receptor","conceptCode":"C126108","definition":"A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"T-Lymphocyte","conceptCode":"C12476","definition":"A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB9226FF-7BB4-6C11-E053-4EBD850A0BC1","latestVersionIndicator":"Yes","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB9226FF-7BC2-6C11-E053-4EBD850A0BC1","latestVersionIndicator":"Yes","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ARCHERJ","dateModified":"2021-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7580669","version":"1","preferredName":"Prior Therapy Agent Type","preferredDefinition":"Prior action or administration of therapeutic agents that produced an effect that is intended to alter or stop a pathologic process._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)_The words or language units by which a thing is known._Something distinguishable as an identifiable class based on common qualities.","longName":"PRI_TX_AGT_TYP","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Investigational","valueDescription":"Investigational New Drug","ValueMeaning":{"publicId":"2959607","version":"1","preferredName":"Investigational New Drug","longName":"2959607","preferredDefinition":"A new drug or biological drug that is used in a clinical investigation. The term also includes a biological product that is used in vitro for diagnostic purposes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Investigational New Drug","conceptCode":"C49135","definition":"A new drug or biological drug that is used in a clinical investigation. The term also includes a biological product that is used in vitro for diagnostic purposes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77FB5264-5E08-80D2-E040-BB89AD4379BB","latestVersionIndicator":"Yes","beginDate":"2009-11-09","endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"MAESKEB","dateModified":"2022-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB92186B-D42C-585C-E053-4EBD850A6723","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","deletedIndicator":"No"},{"value":"Commercial Kymriah","valueDescription":"CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes","ValueMeaning":{"publicId":"5621736","version":"1","preferredName":"CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes","longName":"5621736","preferredDefinition":"Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, CD19CAR-CD3zeta-4-1BB-expressing autologous T-lymphocytes direct the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3-zeta (or CD247) is a transmembrane signaling adaptor polypeptide that regulates the assembly of complete TCR complexes and their expression on the cell surface.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tisagenlecleucel","conceptCode":"C102758","definition":"Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, tisagenlecleucel directs the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3-zeta (or CD247) is a transmembrane signaling adaptor polypeptide that regulates the assembly of complete TCR complexes and their expression on the cell surface.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BD2A-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB92186B-D440-585C-E053-4EBD850A6723","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7580668","version":"1","preferredName":"Prior Therapy Agent Type","preferredDefinition":"An indicator that a person has been previously treated for the same condition or with the same therapy.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.:Something distinguishable as an identifiable class based on common qualities.","longName":"C16124:C1708:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior Therapy","conceptCode":"C16124","definition":"Prior action or administration of therapeutic agents that produced an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB92186B-D3FD-585C-E053-4EBD850A6723","latestVersionIndicator":"Yes","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB92186B-D40E-585C-E053-4EBD850A6723","latestVersionIndicator":"Yes","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ARCHERJ","dateModified":"2021-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What CAR T-cell product was m","type":"Preferred Question Text","description":"What CAR T-cell product was manufactured?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB9226FF-7BD5-6C11-E053-4EBD850A0BC1","latestVersionIndicator":"Yes","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"MAESKEB","dateModified":"2021-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}